FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of a heterodimeric bispecific antibody; it can be used for the prevention or treatment of TNFα and IL-17A-related diseases. The heterodimeric bispecific antibody obtained by a redox method consists of two parts: 1) TNFα antigen-binding domain and the first Fc chain, and 2) IL-17A antigen-binding domain and the second Fc chain.
EFFECT: invention allows for simultaneous blocking of signal paths of TNFα and IL-17A.
26 cl, 14 dwg, 6 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| ANTIBODY AGAINST TNFR2 AND ITS APPLICATION | 2020 |
|
RU2793165C1 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTIBODY AGAINST CD147 | 2018 |
|
RU2785293C2 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| ANTIBODIES AGAINST PROGRAMMED CELL DEATH LIGAND 1 AND THEIR USE | 2020 |
|
RU2786235C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| ANTIBODIES AGAINST SIGLEC-15 AND THEIR APPLICATION METHODS | 2017 |
|
RU2759334C2 |
